Melanoma Antigen Preferentially Expressed in Tumors

Preferred Label : Melanoma Antigen Preferentially Expressed in Tumors;

NCIt synonyms : Preferentially Expressed Antigen of Melanoma; Opa-Interacting Protein 4; Opa-Interacting Protein OIP4; OIP-4; Cancer/Testis Antigen 130; Preferentially Expressed Antigen in Melanoma; PRAME;

NCIt definition : Melanoma antigen preferentially expressed in tumors (509 aa, 58 kDa) is encoded by the human PRAME gene. This protein plays a role in the repression of retinoic acid receptor-dependent gene expression.;

Details

Origin ID

C127930;

UMLS CUI

C1438798;

Automatic exact mappings (from CISMeF team)
- First (Given) name [LOINC component]
- PRAME nuclear receptor transcriptional regulator [HGNC gene]
- Prame nuclear receptor transcriptional regulator [OMIM gene]
OMIM relation
- Prame nuclear receptor transcriptional regulator [OMIM gene]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
UMLS correspondences (same concept)
- Melanoma antigen preferentially expressed in tumors (substance) [SNOMED CT concept]
- PRAME protein, human [MeSH Supplementary Concept]
- PRAME protein, human [MeSH concept]
concept_is_in_subset
- CTRP Biomarker Terminology [NCIt concept]
- CTRP Molecular Genetic Biomarker Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
gene_encodes_gene_product
- PRAME Gene [NCIt concept]
- Regulatory Gene [NCIt concept]
- Transcription Regulation Gene [NCIt concept]
gene_product_has_biochemical_function
- Apoptosis Inhibitor [NCIt concept]
- Transcription Repressor/Corepressor [NCIt concept]
gene_product_has_structural_domain_or_motif
- Leucine-Rich Repeat [NCIt concept]
gene_product_plays_role_in_biological_process
- Negative Regulation of Apoptosis [NCIt concept]
- Negative Regulation of Cell Differentiation [NCIt concept]
- Stimulation of Cell Proliferation [NCIt concept]
- Transcriptional Regulation [NCIt concept]
- Transcriptional Repression [NCIt concept]
is_target
- Anti-PRAME Immunotherapeutic GSK2302032A [NCIt concept]
- Anti-PRAME T-cell Receptor/Anti-CD3 scFv Fusion Protein IMC-F106C [NCIt concept]
- Autologous Anti-PRAME TCR/CD8alphabeta-expressing T-cells IMA203CD8 [NCIt concept]
- Autologous PRAME-targeting TCR-engineered T-cells IMA203 [NCIt concept]
- DNA Vector pPRA-PSM Vaccine [NCIt concept]
- Donor-derived WT1/PRAME/NY-ESO-1/Survivin-specific T-lymphocytes [NCIt concept]
- NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Autologous Cytotoxic T Lymphocytes [NCIt concept]
- Patient-derived WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes [NCIt concept]
- Synthetic Peptides E-PRA And E-PSM Vaccine [NCIt concept]
- WT1/PRAME/Survivin-specific Cytotoxic T-lymphocytes [NCIt concept]
- WT1/PRAME/Survivin-specific T-cells MANA-312 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients